Balaji Amines Ltd
BALAMINESBalaji Amines Ltd is strength at full price. The numbers are improving — and a P/E at the 82nd percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 82nd percentile of its own range you are paying full price for it.
The price is in a confirmed uptrend (10 weeks in) while the P/E sits at the 82nd percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +110.8% year on year, and 138% of the last 3 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Balaji Amines Ltd trades at ₹2,133, in a confirmed uptrend and 10 weeks into that stage. That is +30.5% against its own 200-day average. It sits at 80% of a 52-week range of ₹1,001 to ₹2,415. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a confirmed uptrend — week 10 of stage 2, confirmed. At ₹2,133 it trades +30.5% versus its 200-day average and sits at 80% of its 52-week range (₹1,001–₹2,415).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +1,481% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-24) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Balaji Amines Ltd trades at 33.9× P/E, at the pricey end of its own range (82nd percentile). Its long-run median P/E is 23.8×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 33.9× is at the pricey end of its own range (82nd percentile), against a long-run median of 23.8× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +6.1% against a +26.1% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the −8.2%/yr price move, ~−3.0%/yr came from earnings growth and ~−5.2 pp from the multiple (compressing); over 10y, of the +21.9%/yr price move, ~+13.5%/yr came from earnings growth and ~+8.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 25% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Balaji Amines Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −31.9% at the trough to +41.6%, a 4-quarter improving streak, ROCE slipping at 11.0%. The read is built from 8 quarters across 4 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +2.2% | −15.4% | +1.6% | +8.3% |
| Profit | +6.3% | −25.3% | −7.0% | +11.3% |
| EPS | +6.1% | −19.9% | −6.8% | +11.2% |
| Share price | +26.1% | −0.7% | −8.2% | +21.9% |
4-Factor Sector Score
64.9/100 — rank 2 of 20 in Chemicals - Organic · 82% evidence confidence
Balaji Amines Ltd scores 64.9 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 26.7 + 13.2 + 6.6 + 18.4 = 64.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Balaji Amines Ltd reported ₹456 Cr of revenue in the Jun 26 quarter, +27.4% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 8.3% a year. The last full year, FY26, came in at ₹1,419 Cr. The last four reported quarters add to ₹1,523 Cr.
FY26 revenue came in at ₹1,419 Cr (+2.2% on the year), capping 10 years at 8.3% compound. The latest quarter (Jun 26) printed ₹456 Cr, +27.4% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +10.8% growth against the decade's 8.3% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +11.1% over the last 4 quarters against −1.3%/yr over the last 8 — accelerating; TTM profit +41.6% vs +0.2%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Balaji Amines Ltd's operating margin is 25.0% in the Jun 26 quarter, +10.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 15.0% to 29.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 25.0%, +10.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 15.0%–29.0%.
Why the margin moved: operating margin went +10.2 pp year on year while gross margin went +3.7 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Balaji Amines Ltd earned ₹78.0 Cr of net profit in the Jun 26 quarter, +110.8% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹169 Cr. The 10-year compound rate is 11.3%. That is 17.1% of the quarter's revenue. The same quarter a year earlier earned ₹37.0 Cr.
Jun 26 profit was ₹78.0 Cr, +110.8% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹169 Cr (+6.3%), and the 10-year compound rate is 11.3%.
Why profit moved: revenue contributed +27.4% and the margin +10.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +40.9% vs revenue +10.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 138% of Balaji Amines Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹184 Cr of operating cash against ₹169 Cr of profit. After ₹370 Cr of capital spending, ₹−186 Cr was left as free cash.
FY26: operating cash of ₹184 Cr against reported profit of ₹169 Cr, leaving free cash of ₹−186 Cr after ₹370 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 138% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 138%: the cash cycle stretched 59 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 5.4× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Balaji Amines Ltd's cash conversion cycle runs 163 days in FY26, up from 104 days in FY21. Capital spending ran ₹811 Cr over the last 3 years. At FY26 sales of ₹1,419 Cr each day of that cycle holds about ₹3.9 Cr, so roughly ₹634 Cr sits inside the business at any moment.
FY26: debtors at 89 days, inventory at 113 days — roughly 3.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 163 days, looser than FY21's 104.
The full loop: cash goes out to suppliers and production on day 0; stock waits 113 days to sell; customers pay about 89 days after that; and suppliers themselves are paid at 39 days — netting out to the 163-day cycle.
In money terms: at FY26 sales of ₹1,419 Cr, each day of the cycle holds about ₹3.9 Cr — so the 163-day loop keeps roughly ₹634 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹811 Cr over the last 3 fiscal years against ₹149 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹512 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Balaji Amines Ltd earns a ROCE of 11% in FY26. That is up from a trough of 11% in FY25. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 11.9% net margin on 0.52× asset turns.
FY26 ROCE is 11%, recovered from a FY25 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 11.9% net margin × 0.52× asset turns × 1.39× balance-sheet leverage ≈ 8.6% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 25% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Balaji Amines Ltd carries ₹133 Cr of borrowings against ₹1,976 Cr of equity in FY26, a debt-to-equity of 0.07. Operating profit covers the interest bill 53×. Over 5 years borrowings went from ₹127 Cr to ₹133 Cr. Capital spending ran ₹811 Cr across the last 3 of those years.
FY26: borrowings of ₹133 Cr against equity of ₹1,976 Cr — a debt-to-equity of 0.07. Operating profit covers the interest bill 53×. Over 5 years borrowings went from ₹127 Cr to ₹133 Cr while capital spending ran ₹811 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 25% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 1.9 points of Balaji Amines Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 3.2% of the company. Promoters moved +0.9 points over the same window, to 54.6%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −1.9 points over 8 quarters to 3.2%; Promoters: +0.9 points over 8 quarters to 54.6%; Domestic institutions: +0.0 points over 8 quarters to 1.6%.
🚨 Why the register moved: foreign institutions drove it (−1.9 points), absorbed on the other side by promoters (+0.9 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Balaji Amines Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Nitta Gelatin India LtdKERALACHEM | 82.3/100Sector-leading setup78% evidence | 27.8/35 Revenue 11.8% · PAT 34.1% · OPM change 10 pp 83% evidence | 20.2/25 ROCE 31.3% · OPM 28% 76% evidence | 14.3/20 P/E 13.5× · PEG — 50% evidence | 20.0/20 RS sector 71.7% · RS bench 85.7% · 1Y 75.4%4 of 4 weeks ahead to 2026-06-07 100% evidence | |
| Exact sum: 27.8 + 20.2 + 14.3 + 20 = 82.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Balaji Amines Ltdthis pageBALAMINES | 64.9/100Mixed-positive evidence82% evidence | LEADER | 26.7/35 Revenue 11.1% · PAT 41.6% · OPM change 10 pp 95% evidence | 13.2/25 ROCE 11% · OPM 25% 76% evidence | 6.6/20 P/E 33.9× · PEG — 50% evidence | 18.4/20 RS sector 27.9% · RS bench 45.8% · 1Y 26.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.7 + 13.2 + 6.6 + 18.4 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3OCCL LtdOCCLLTD | 62.1/100Mixed-positive evidence60% evidence | TURNING | 26.2/35 Revenue 40.6% · PAT 100% · OPM change 7 pp 95% evidence | 12.1/25 ROCE 12.8% · OPM 28% 76% evidence | 11.5/20 P/E 10.9× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 46.7% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 26.2 + 12.1 + 11.5 + 12.3 = 62.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Shri Ahimsa Naturals LtdSHRIAHIMSA | 60.8/100Thin evidence · provisional56% evidence | LEADER | 18.9/35 Revenue — · PAT — · OPM change -2 pp 26% evidence | 17.8/25 ROCE 21.7% · OPM 28% 95% evidence | 10.3/20 P/E 30.9× · PEG — 15% evidence | 13.8/20 RS sector 22.1% · RS bench 40.5% · 1Y 114.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 17.8 + 10.3 + 13.8 = 60.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Indo Amines LtdINDOAMIN | 59.8/100Mixed-positive evidence77% evidence | TURNING | 22.5/35 Revenue 7.6% · PAT 42.9% · OPM change 2 pp 83% evidence | 16.0/25 ROCE 19.9% · OPM 11% 95% evidence | 13.9/20 P/E 11.7× · PEG — 50% evidence | 7.4/20 RS sector -12.9% · RS bench 0.5% · 1Y -15%10 of 10 weeks ahead 70% evidence |
| Exact sum: 22.5 + 16 + 13.9 + 7.4 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Foseco India LtdFOSECOIND | 57.4/100Mixed-positive evidence83% evidence | TURNING | 18.6/35 Revenue 26.9% · PAT 7.5% · OPM change 2 pp 88% evidence | 14.9/25 ROCE 17.4% · OPM 20% 100% evidence | 11.1/20 P/E 39.7× · PEG 1.31 65% evidence | 12.8/20 RS sector 22.8% · RS bench -2.4% · 1Y 5.3%4 of 10 weeks ahead 70% evidence |
| Exact sum: 18.6 + 14.9 + 11.1 + 12.8 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Elantas Beck India LtdELANTAS | 50.5/100Mixed-positive evidence72% evidence | ASLEEP | 17.2/35 Revenue 11.1% · PAT 6.6% · OPM change 0 pp 83% evidence | 17.9/25 ROCE 21.2% · OPM 20% 76% evidence | 7.5/20 P/E 50.9× · PEG — 50% evidence | 7.9/20 RS sector -7.6% · RS bench -2.3% · 1Y -26%1 of 7 weeks ahead 70% evidence |
| Exact sum: 17.2 + 17.9 + 7.5 + 7.9 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Laxmi Organic Industries LtdLXCHEM | 48.2/100Mixed-negative evidence94% evidence | TURNING | 20.8/35 Revenue 5.5% · PAT 26% · OPM change 7.6 pp 100% evidence | 8.2/25 ROCE 4.7% · OPM 12% 100% evidence | 11.8/20 P/E 39.4× · PEG 1.14 100% evidence | 7.4/20 RS sector -20.5% · RS bench 6.3% · 1Y -13.2%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.8 + 8.2 + 11.8 + 7.4 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Valiant Organics LtdVALIANTORG | 46.9/100Mixed-negative evidence83% evidence | ASLEEP | 23.0/35 Revenue 2.6% · PAT 100% · OPM change 2 pp 83% evidence | 9.6/25 ROCE 5.5% · OPM 12% 95% evidence | 11.4/20 P/E 25.7× · PEG — 50% evidence | 2.9/20 RS sector -18.7% · RS bench -6.3% · 1Y -29.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23 + 9.6 + 11.4 + 2.9 = 46.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.7% and the one-year return is -29.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 10Shree Ganesh Remedies LtdSGRL | 46.6/100Thin evidence · provisional57% evidence | 11.3/35 Revenue -17.3% · PAT -37.7% · OPM change -4.8 pp 53% evidence | 16.4/25 ROCE 19.2% · OPM 31.9% 57% evidence | 8.9/20 P/E 35.1× · PEG — 50% evidence | 10.0/20 RS sector 2.3% · RS bench -9.9% · 1Y -15.8%4 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 11.3 + 16.4 + 8.9 + 10 = 46.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Fairchem Organics LtdFAIRCHEMOR | 44.4/100Mixed-negative evidence87% evidence | BREAKING OUT | 18.4/35 Revenue 0% · PAT 50% · OPM change 6 pp 95% evidence | 5.7/25 ROCE 3.3% · OPM 10% 95% evidence | 6.0/20 P/E 66.4× · PEG — 50% evidence | 14.3/20 RS sector 1.2% · RS bench 16.6% · 1Y -12.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 5.7 + 6 + 14.3 = 44.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Fine Organic Industries LtdFINEORG | 43.3/100Mixed-negative evidence96% evidence | FADING | 13.8/35 Revenue 4.2% · PAT 1.7% · OPM change 1 pp 88% evidence | 18.0/25 ROCE 21.5% · OPM 21% 100% evidence | 6.0/20 P/E 36.2× · PEG 2.7 100% evidence | 5.5/20 RS sector -10.6% · RS bench 3.4% · 1Y -7.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 18 + 6 + 5.5 = 43.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13GFL LtdGFLLIMITED | 43.0/100Mixed-negative evidence62% evidence | 20.6/35 Revenue 0% · PAT 100% · OPM change 2562 pp 62% evidence | 6.3/25 ROCE 2.1% · OPM 19% 95% evidence | 11.3/20 P/E 11× · PEG — 15% evidence | 4.8/20 RS sector -14.7% · RS bench -16.8% · 1Y -28.6%1 of 8 weeks ahead 70% evidence | |
| Exact sum: 20.6 + 6.3 + 11.3 + 4.8 = 43 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14BASF India LtdBASF | 40.7/100Mixed-negative evidence90% evidence | ASLEEP | 11.9/35 Revenue -0.4% · PAT -12.5% · OPM change 1.7 pp 88% evidence | 9.3/25 ROCE 14.5% · OPM 3.2% 100% evidence | 12.2/20 P/E 38.1× · PEG 1.62 100% evidence | 7.3/20 RS sector -4.4% · RS bench -8.7% · 1Y -28%1 of 11 weeks ahead 70% evidence |
| Exact sum: 11.9 + 9.3 + 12.2 + 7.3 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Oriental Aromatics LtdOAL | 38.5/100Mixed-negative evidence74% evidence | TURNING | 13.0/35 Revenue 13.5% · PAT -77.7% · OPM change -0.4 pp 95% evidence | 7.2/25 ROCE 4.5% · OPM 7.6% 95% evidence | 8.7/20 P/E 231× · PEG — 15% evidence | 9.6/20 RS sector -9.8% · RS bench 15.9% · 1Y -3.1%9 of 10 weeks ahead 70% evidence |
| Exact sum: 13 + 7.2 + 8.7 + 9.6 = 38.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Gem Aromatics LtdGEMAROMA | 31.4/100Thin evidence · provisional56% evidence | TURNING | 4.3/35 Revenue -27.3% · PAT -80% · OPM change -8.4 pp 83% evidence | 8.6/25 ROCE 3.4% · OPM 14.2% 95% evidence | 8.5/20 P/E 705× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence |
| Exact sum: 4.3 + 8.6 + 8.5 + 10 = 31.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Sigachi Industries LtdSIGACHI | 25.4/100Adverse evidence77% evidence | TURNING | 6.2/35 Revenue -2.1% · PAT -80% · OPM change -8.8 pp 83% evidence | 6.9/25 ROCE 6.2% · OPM 13.5% 95% evidence | 8.5/20 P/E 30.4× · PEG — 50% evidence | 3.8/20 RS sector -35.5% · RS bench -8.5% · 1Y -33.6%7 of 10 weeks ahead 70% evidence |
| Exact sum: 6.2 + 6.9 + 8.5 + 3.8 = 25.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Sacheerome LtdSACHEEROME | 59.9/100Thin evidence · provisional41% evidence | TURNING | 17.4/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 20.6/25 ROCE 35.7% · OPM 23% 95% evidence | 10.2/20 P/E 33.3× · PEG — 15% evidence | 11.7/20 RS sector — · RS bench 30.9% · 1Y 141.7%3 of 10 weeks ahead 25% evidence |
| Exact sum: 17.4 + 20.6 + 10.2 + 11.7 = 59.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Jyoti Resins and Adhesives LtdJYOTIRES | 46.1/100Thin evidence · provisional50% evidence | 13.2/35 Revenue 8.7% · PAT -5.5% · OPM change -6 pp 53% evidence | 18.7/25 ROCE 50% · OPM 26% 57% evidence | 10.8/20 P/E 14.3× · PEG — 15% evidence | 3.4/20 RS sector -20.6% · RS bench -30.3% · 1Y -40.3%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 13.2 + 18.7 + 10.8 + 3.4 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Citurgia Biochemicals LtdCITURGIA | 41.1/100Thin evidence · provisional18% evidence | 14.3/35 Revenue — · PAT -30.4% · OPM change — 18% evidence | 6.8/25 ROCE -2150% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 14.3 + 6.8 + 10 + 10 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Balaji Amines Ltd's share price today?
Balaji Amines Ltd trades at ₹2,133, +26.1% over the past year. The company is valued at ₹6,912 Cr. The stock sits at 80% of its 52-week range of ₹1,001–₹2,415, +30.5% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 10 weeks in. — as of 31 July 2026.
What were Balaji Amines Ltd's latest quarterly results?
Balaji Amines Ltd reported revenue of ₹456 Cr and net profit of ₹78.0 Cr for the Jun 26 quarter. Revenue rose 27.4% and profit rose 110.8% year on year. Earnings per share were ₹23.13. The operating margin was 25.0%, 10.0 pp higher than a year earlier. — as of 31 July 2026.
What is Balaji Amines Ltd's revenue?
Balaji Amines Ltd reported revenue of ₹456 Cr in the Jun 26 quarter, +27.4% year on year. For the full FY26 fiscal year, revenue was ₹1,419 Cr (+2.2%). Over the last 10 years revenue compounded at 8.3% a year. — as of 31 July 2026.
What is Balaji Amines Ltd's profit?
Balaji Amines Ltd earned ₹78.0 Cr of net profit in the Jun 26 quarter, +110.8% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹169 Cr. The operating margin ran 25.0% in the latest quarter. — as of 31 July 2026.
What is Balaji Amines Ltd's market cap?
Balaji Amines Ltd's market capitalisation is ₹6,912 Cr at a share price of ₹2,133. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Balaji Amines Ltd's P/E ratio?
Balaji Amines Ltd trades at a P/E of 33.9×, at the 82nd percentile of its own 10-year range, against a long-run median of 23.8×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Balaji Amines Ltd pay a dividend?
Yes — Balaji Amines Ltd's dividend payout was 21% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Balaji Amines Ltd overvalued?
On its own history, Balaji Amines Ltd looks expensive against its own history: its P/E of 33.9× sits at the 82nd percentile of its 10-year range (long-run median 23.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Balaji Amines Ltd growing?
Yes — Balaji Amines Ltd is growing: latest-quarter revenue +27.4% year on year, profit +110.8%, and the margin +10.0 pp at 25.0%. The 10-year compound rates are 8.3% (revenue) and 11.3% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Balaji Amines Ltd performing?
Balaji Amines Ltd is in a confirmed uptrend, 10 weeks in. Its latest quarter's revenue rose 27.4% and profit rose 110.8% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Balaji Amines Ltd in?
Turning around — profit growth swung from −31.9% at the trough to +41.6%, a 4-quarter improving streak, ROCE slipping at 11.0%. The read comes from the last 12 quarters of growth (revenue growth +11.1% latest, profit growth +41.6% latest, eps growth +34.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Balaji Amines Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 10 of stage 2), trading +30.5% versus its 200-day average and at 80% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Balaji Amines Ltd beating the market?
Not lately — on a trailing-13-week view Balaji Amines Ltd is currently behind the NIFTY 500 (1 week and counting; last ahead the week of 2026-07-24), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +1,481% against the NIFTY 500's +276% — ahead of the index over the full window. — as of 31 July 2026.
Will Balaji Amines Ltd's share price go up?
This page publishes no price forecast for Balaji Amines Ltd. What it measures instead: the share price is ₹2,133, the price is in a confirmed uptrend 10 weeks in. Its P/E of 33.9× sits at the 82nd percentile of its own 10-year range. — as of 31 July 2026.
Who owns Balaji Amines Ltd?
Promoters hold 54.6% of Balaji Amines Ltd, foreign institutions 3.2%, domestic institutions 1.6% and the public 40.7% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 1.9 points over 8 quarters. — as of 31 July 2026.
Does Balaji Amines Ltd have too much debt?
No — Balaji Amines Ltd's debt-to-equity is 0.07, and operating profit covers the interest bill 53×. FY26 borrowings were ₹133 Cr against equity of ₹1,976 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Balaji Amines Ltd's capex?
Balaji Amines Ltd spent ₹811 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹370 Cr, with ₹512 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Balaji Amines Ltd's cash flow?
Balaji Amines Ltd generated ₹184 Cr of operating cash flow in FY26 and ₹−186 Cr of free cash flow after ₹370 Cr of capital spending. Reported profit that year was ₹169 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Balaji Amines Ltd's profit real cash?
Yes — over the last 3 fiscal years, 138% of Balaji Amines Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹184 Cr against reported profit of ₹169 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Balaji Amines Ltd in its business cycle?
Balaji Amines Ltd's FY26 operating margin was 19.0%, against a 13-year band of 15.0%–29.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 25.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Balaji Amines Ltd story?
The sharpest disagreement: the engine is strong, but at the 82nd percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Balaji Amines Ltd a stock worth studying right now?
This is not investment advice. The machine read: Balaji Amines Ltd is strength at full price. The numbers are improving — and a P/E at the 82nd percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.